상세 보기
Identification of ROS1 Rearrangement in Gastric Adenocarcinoma
- Lee, Jeeyun;
- Lee, Seung Eun;
- Kang, So Young;
- Do, In-Gu;
- Lee, Sujin;
- ... Kim, Kyoung-Mee;
- 외 5명
WEB OF SCIENCE
99SCOPUS
118초록
BACKGROUND: Recently, chromosomal rearrangements involving receptor tyrosine kinases (RTKs) have been described in common epithelial malignancies, including nonsmall cell lung cancer (NSCLC), colorectal cancer, and breast cancer. One of these RTKs, c-ros oncogene 1, receptor tyrosine kinase (ROS1), has been identified as a driver mutation in NSCLC, because its inhibition by crizotinib, an anaplastic lymphoma receptor tyrosine kinase (ALK)/met proto-oncogene hepatocyte growth factor receptor (MET)/ROS1 inhibitor, led to significant tumor shrinkage in ROS1-rearranged NSCLC. Currently, only human epidermal growth factor 2 (HER2)-targeted therapy in combination with chemotherapy has been successful in significantly prolonging the survival of patients with advanced gastric cancer (GC). There is a need for the discovery of additional novel targets in GC. METHODS: Anti-ROS1 immunohistochemistry (IHC) was used to screen 495 GC samples and was followed by simultaneous ROS1 break-apart fluorescence in situ hybridization (FISH) and reverse transcriptase-polymerase chain reaction (RT-PCR) analyses in IHC-positive samples. Fusion partners in ROS1-rearranged GC were determined by RT-PCR. In all 495 samples, HER2 amplification was identified with FISH, and MET expression was identified by IHC. RESULTS: Twenty-three tumor samples were ROS1 IHC-positive. Three of 23 patients were ROS1 FISH positive, HER2 FISH negative, and negative for MET overexpression; and 2 of those 3 patients harbored a solute carrier family 34 (sodium phosphate), member 2 (SLC34A2)-ROS1 fusion transcripts. No fusion partner was identified in the third patient. Both patients who had SLC34A2-ROS1 transcripts had poorly differentiated histology with recurrence and death within 2 years of curative surgery. ROS1 IHC-positive status was not identified as an independent prognostic factor for overall survival. CONCLUSIONS: In this study, an SLC34A2-ROS1 rearrangement was identified in GC, and the results provide a rationale for investigating the clinical efficacy of ROS1 inhibitors in this unique molecular subset of GC. Cancer 2013; 119: 1627-35. (C) 2013 American Cancer Society.
키워드
- 제목
- Identification of ROS1 Rearrangement in Gastric Adenocarcinoma
- 저자
- Lee, Jeeyun; Lee, Seung Eun; Kang, So Young; Do, In-Gu; Lee, Sujin; Ha, Sang Yun; Cho, Jeonghee; Kang, Won Ki; Jang, Jiryeon; Ou, Sai-Hong Ignatius; Kim, Kyoung-Mee
- 발행일
- 2013-05-01
- 유형
- Article
- 저널명
- Cancer
- 권
- 119
- 호
- 9
- 페이지
- 1627 ~ 1635
- 언어
- ENG
- 출판사
- John Wiley & Sons Inc.
- 발행국가
- 미국
- 분량
- 9 페이지
- ISSN
- E 1097-0142
P 0008-543X